Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Stopped early · Phase 2
Conditions studied: Lung Cancer
In brief
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with cisplatin and etoposide works in treating patients with extensive-stage small cell lung cancer.
Key facts
- Study ID
- NCT00726986
- Run by
- Afshin Dowlati, MD
- People needed
- 18
- Starts
- 2008-07-01
- Expected to finish
- 2012-07-01
- Last updated by the study team
- 2014-11-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Columbia Presbyterian — New York, New York, United States
- Lake/University Ireland Cancer Center — Cleveland, Ohio, United States
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
- MetroHealth Medical Center — Cleveland, Ohio, United States
- CCF-Fairview Hospital — Cleveland, Ohio, United States
- UHHS Chagrin Highlands Medical Center — Cleveland, Ohio, United States
- Southwest General Health Center — Cleveland, Ohio, United States
- UHHS Westlake Medical Center — Cleveland, Ohio, United States
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
- UH-Monarch — Mayfield Heights, Ohio, United States
- UH-Firelands — Sandusky, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.